cas 95306-64-2|| where to buy 4-Amino-2-hydroxy-5-methylpyridine

Nom du produit:4-Amino-2-hydroxy-5-methylpyridine

IUPAC Name:4-amino-5-methyl-1,2-dihydropyridin-2-one

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM120752-100g	in stock	ǊƀȬ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 95306-64-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:95306-64-2; Formule moléculaire:C6H8N2O; Point de fusion:-; Code SMILES:O=C1C=C(N)C(=CN1)C; Densité:

: Numéro de catalogue:CM120752; Poids moléculaire:124.14; Point d'ébullition:; N° Mdl:MFCD18384902; Stockage:Keep in dark place, store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Finerenone; Bayer announced that FINEARTS-HF met its primary endpoint, achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits. The randomized, double-blind, placebo-controlled, parallel-group, multi-center phase III cardiovascular outcomes study evaluated the efficacy and safety of KERENDIA® (finerenone) for investigational new use in patients with HF with a LVEF≥40% (left ventricular ejection fraction). Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (MRA) that was approved to reduce the risk of cardiovascular death, non-fatal myocardial infarction, hospitalization for heart failure, sustained eGFR decline, and end-stage kidney disease in adult patients with CKD associated with T2D.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.